Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03710603 · FLOW

Participant flow

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma · Source last updated 2026-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Arm A: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.
    id
    FG000
    title
    Velcade Lenalidomide Dexamethasone (VRd)
  2. description
    Arm B: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with subcutaneous daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by subcutaneous daratumumab in combination with lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.
    id
    FG001
    title
    Daratumumab + VRd (D-VRd)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        44
      2. group Id
        FG001
        num Subjects
        34
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        5
      type
      Lost to Follow-up
    4. reasons
      1. group Id
        FG000
        num Subjects
        11
      2. group Id
        FG001
        num Subjects
        10
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        354
      2. group Id
        FG001
        num Subjects
        355
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        295
      2. group Id
        FG001
        num Subjects
        306
      comment
      Participants that are still on study are listed as "completed"
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        59
      2. group Id
        FG001
        num Subjects
        49
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Arm A: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.
    id
    FG000
    title
    Velcade Lenalidomide Dexamethasone (VRd)
  2. description
    Arm B: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with subcutaneous daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by subcutaneous daratumumab in combination with lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.
    id
    FG001
    title
    Daratumumab + VRd (D-VRd)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        44
      2. group Id
        FG001
        num Subjects
        34
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        5
      type
      Lost to Follow-up
    4. reasons
      1. group Id
        FG000
        num Subjects
        11
      2. group Id
        FG001
        num Subjects
        10
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        354
      2. group Id
        FG001
        num Subjects
        355
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        295
      2. group Id
        FG001
        num Subjects
        306
      comment
      Participants that are still on study are listed as "completed"
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        59
      2. group Id
        FG001
        num Subjects
        49
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice